- Conditions
- Relapsed and Refractory Multiple Myeloma (RRMM)
- Interventions
- Non-Interventional
- Other
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Tarrytown, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 481–504
of 865
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Relapsed and/or Refractory Multiple Myeloma
- Interventions
- AMG 420
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 4
- States / cities
- Park Ridge, Illinois • Boston, Massachusetts • New York, New York + 1 more
- Conditions
- Multiple Myeloma
- Interventions
- PCI-32765, Dexamethasone
- Drug
- Lead sponsor
- Pharmacyclics LLC.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 11
- States / cities
- La Jolla, California • Baltimore, Maryland • Boston, Massachusetts + 7 more
- Conditions
- Multiple Myeloma
- Interventions
- bortezomib
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 620 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2004
- U.S. locations
- 39
- States / cities
- Berkeley, California • Duarte, California • La Jolla, California + 30 more
- Conditions
- Plasma Cell Myeloma Refractory
- Interventions
- Isatuximab SC-OBDS, Montelukast, Dexamethasone, Acetaminophen, Diphenhydramine, Methylprednisolone, Carfilzomib
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 34
- States / cities
- Phoenix, Arizona • Los Angeles, California • West Hollywood, California + 29 more
- Conditions
- Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Interventions
- anti-thymocyte globulin, fludarabine phosphate, Melphalan, mycophenolate mofetil, tacrolimus, umbilical cord blood transplantation
- Biological · Drug · Procedure
- Lead sponsor
- Northside Hospital, Inc.
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- Interventions
- bortezomib, immunologic technique, samarium Sm 153 lexidronam pentasodium
- Drug · Other · Radiation
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
- Conditions
- Recurrent Multiple Myeloma, Refractory Multiple Myeloma
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Cyclophosphamide, Dexamethasone, Echocardiography, Isatuximab, Questionnaire Administration, Universal Donor Expanded TGF-beta-imprinted NK Cells
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- Elvira Umyarova
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Multiple Myeloma
- Interventions
- Cevostamab, Tocilizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 9
- States / cities
- Aurora, Colorado • Jacksonville, Florida • Baltimore, Maryland + 5 more
- Conditions
- Multiple Myeloma
- Interventions
- BT062
- Drug
- Lead sponsor
- Biotest Pharmaceuticals Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Chicago, Illinois • Boston, Massachusetts + 2 more
- Conditions
- Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Interventions
- bortezomib, vorinostat, laboratory biomarker analysis, pharmacological study
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Chronic Lymphocytic Leukemia, Multiple Myeloma, Acute Myeloid Leukemia
- Interventions
- LAVA-051, Interleukin 2
- Biological
- Lead sponsor
- Lava Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • New York, New York • Charlotte, North Carolina + 2 more
- Conditions
- Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
- Interventions
- Laboratory Biomarker Analysis, Lenalidomide, Nivolumab, Pharmacological Study
- Other · Drug · Biological
- Lead sponsor
- Yvonne Efebera
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Multiple Myeloma
- Interventions
- TH-302, TH-302 and Dexamethasone, TH-302 Dose Escalation and Dexamethasone in Combination with Bortezomib, TH-302 Dose Escalation and Dexamethasone in Combination with Pomalidomide
- Drug
- Lead sponsor
- Threshold Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 10
- States / cities
- Monterey, California • Tampa, Florida • Scarborough, Maine + 5 more
- Conditions
- Multiple Myeloma
- Interventions
- busulfan, melphalan, fludarabine, anti-thymocyte globulin (ATG), a T cell depleted stem cell transplant
- Drug · Biological · Procedure
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 21 Years to 72 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2025
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Multiple Myeloma
- Interventions
- Pomalidomide, Bortezomib, Dexamethasone
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 559 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2022
- U.S. locations
- 92
- States / cities
- Mobile, Alabama • Tucson, Arizona • Berkeley, California + 68 more
- Conditions
- Multiple Myeloma
- Interventions
- ONC201, Ixazomib, Dexamethasone
- Drug
- Lead sponsor
- Ajai Chari
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Multiple Myeloma
- Interventions
- Pomalidomide, Pegylated Liposomal Doxorubicin (PLD), Dexamethasone
- Drug
- Lead sponsor
- Oncotherapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 8
- States / cities
- Burbank, California • Encinitas, California • Fresno, California + 5 more
- Conditions
- Multiple Myeloma
- Interventions
- SEA-BCMA, dexamethasone, pomalidomide
- Drug
- Lead sponsor
- Seagen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 13
- States / cities
- Palo Alto, California • Aurora, Colorado • Miami, Florida + 10 more
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Infection, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Precancerous Condition, Secondary Myelofibrosis, Small Intestine Cancer
- Interventions
- anti-thymocyte globulin, cyclophosphamide, etoposide, fludarabine phosphate, melphalan, methotrexate, sirolimus, tacrolimus, allogeneic hematopoietic stem cell transplantation, hematopoietic stem cell transplantation, nonmyeloablative allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, total-body irradiation
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 2 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 2
- States / cities
- Phoenix, Arizona • Duarte, California
- Conditions
- Cancer
- Interventions
- therapeutic allogeneic lymphocytes
- Biological
- Lead sponsor
- University of Medicine and Dentistry of New Jersey
- Other
- Eligibility
- Not listed
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2011
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
- Conditions
- Multiple Myeloma, Relapsed, Multiple Myeloma, Refractory to Standard Treatment
- Interventions
- Total Marrow Irradiation, Melphalan, Filgrastim (G-CSF), Autologous transplant
- Radiation · Drug · Procedure
- Lead sponsor
- University of Illinois Chicago
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Interventions
- allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation, nonmyeloablative allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
- Procedure
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- Up to 70 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Multiple Myeloma, Plasma Cell Neoplasm, Malignant Plasma Cell Neoplasm
- Interventions
- Radiation Therapy
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas